Nirogy Therapeutics
Latest round
- Series A
Last raised
- Jan 2021
Total raised
- $17M
Investors
- 2
About Nirogy Therapeutics
Based in Massachusetts, US, and founded in 2013, Nirogyone Therapeutics develops novel small molecules to target cellular transport. The company was awarded a USD 2 million NIH/NCI SBIR grant to develop dual monocarboxylate transport inhibitors (dMCTi) for Triple Negative Breast Cancer (TNBC) in September 2020. Nirogy Therapeutics, Inc. has 4 employees across all its locations. The Company's products are SLCTs (Solute Carrier Transporters) which help to control the import and export of various molecules cells in our body and MCTs (Monocarboxylate Transporters) focus on blocking lactate export, which kills cancer cells. Nirogy Therapeutics plans to use the proceeds to advance its drug discovery platform to generate a pipeline of small-molecule drugs designed to target the solute carrier family of transporter proteins (SLCTs) embedded in the cell membrane.
Who invested in Nirogy Therapeutics
2 investors across 1 round
See all investors in Nirogy Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jan 24, 2021
Amount
$17M
Investors
Questions about Nirogy Therapeutics
Who invested in Nirogy Therapeutics?
Nirogy Therapeutics has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Nirogy Therapeutics raised?
Nirogy Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Nirogy Therapeutics last raise money?
Nirogy Therapeutics's most recent round on record is a Series A, in Jan 2021.
What does Nirogy Therapeutics do?
Based in Massachusetts, US, and founded in 2013, Nirogyone Therapeutics develops novel small molecules to target cellular transport.
Where is Nirogy Therapeutics headquartered?
Nirogy Therapeutics is headquartered in Natick, US.
Which VCs invest in companies like Nirogy Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Nirogy Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Nirogy Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.